Multinational pharmaceutical company Cipla Australia says several key banner groups have come onboard to sell Respiri Limited’s (ASX:RSH) wheezo wheeze-detection device, which Cipla is supplying to select pharmacies to help asthma patients better manage their conditions.
“It is terrific to see a product like wheezo now available,” says Azhar Ibrahim, managing director of Cipla Australia.
“Our sales representatives have already received some very enthusiastic and encouraging feedback from pharmacists, with them very eager to have wheezo on their shelves and more importantly in the hands of patients that need it.”
wont be long and it will be flying of the shelves
RSH Price at posting:
17.0¢ Sentiment: Buy Disclosure: Held
